Analysis of 27 Patients in Whom Lymphoscintigraphy Failed to Identify LNs
| Characteristic | Patient | Percentage |
| Sex | ||
| Female | 27 | 100% |
| Age | ||
| ≤50 | 10 | 37.04% |
| >50 | 17 | 62.96% |
| Left or right cancer | ||
| Left | 17 | 62.96% |
| Right | 10 | 37.04% |
| Imaging time | ||
| 2–4 h after injection | 13 | 48.15% |
| 16–18 h after injection | 14 | 51.85% |
| Primary tumor site | ||
| Upper inner quadrant | 26 | 96.30% |
| Lower inner quadrant | 7 | 25.93% |
| Upper outer quadrant | 49 | 181.48% |
| Lower outer quadrant | 16 | 59.26% |
| Central portion | 2 | 7.41% |
| Histopathologic type | ||
| Ductal | 24 | 88.89% |
| Lobular | 1 | 3.70% |
| Other | 2 | 7.41% |
| Clinical T stage | ||
| T1 | 10 | 37.04% |
| T2 | 16 | 59.26% |
| T3 | 1 | 3.70% |
| ER/PR/HER2 | ||
| +/+/+ | 5 | 18.52% |
| −/−/+ | 4 | 14.81% |
| +/−/− or −/+/− or +/+/− | 14 | 51.85% |
| +/−/+ or −/+/+ | 3 | 11.11% |
| −/−/− | 1 | 3.70% |
| Pathology of SLN | ||
| Metastatic SLN | 19 | 70.37% |
| Nonmetastatic SLN | 8 | 29.63% |
ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor-2.